2,032,680 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Norges Bank

Norges Bank acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, Holdings Channel reports. The fund acquired 2,032,680 shares of the biopharmaceutical company’s stock, valued at approximately $662,837,000.

Other hedge funds also recently made changes to their positions in the company. Teacher Retirement System of Texas grew its holdings in shares of Alnylam Pharmaceuticals by 3.2% during the second quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock worth $11,872,000 after buying an additional 1,123 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in Alnylam Pharmaceuticals by 33.0% during the 2nd quarter. Envestnet Asset Management Inc. now owns 95,796 shares of the biopharmaceutical company’s stock worth $31,238,000 after acquiring an additional 23,749 shares during the period. Simon Quick Advisors LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $222,000. Strs Ohio acquired a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $7,781,000. Finally, Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $243,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ALNY shares. Jefferies Financial Group lowered their price objective on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 8th. Stifel Nicolaus boosted their price target on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the stock a “buy” rating in a research note on Monday, October 6th. HC Wainwright set a $570.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, November 4th. Finally, BMO Capital Markets boosted their target price on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Twenty-three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $482.17.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $451.27 on Friday. The firm has a 50 day moving average of $455.81 and a 200-day moving average of $396.74. The company has a market cap of $59.62 billion, a price-to-earnings ratio of -182.70 and a beta of 0.30. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 3,022 shares of the firm’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56. Following the completion of the transaction, the executive vice president owned 20,221 shares in the company, valued at $9,129,377.08. This trade represents a 13.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 10,000 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $451.27, for a total transaction of $4,512,700.00. Following the completion of the sale, the chief executive officer owned 65,409 shares in the company, valued at $29,517,119.43. This represents a 13.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 78,328 shares of company stock valued at $35,705,793 in the last 90 days. 1.50% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.